Mitsuhide Naruse

Mitsuhide Naruse


Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009
Verified
Journal Article
Closed access
TOToshio Ogihara
Toshio Ogihara
KKKenjiro Kikuchi
Kenjiro Kikuchi
HMHiroaki Matsuoka
Hiroaki Matsuoka
TFToshiro Fujita
Toshiro Fujita
JHJitsuo Higaki
Jitsuo Higaki
JCJapanese Society of Hypertension Committee
Japanese Society of Hypertension Committee

21 May 2021 in Nature Reviews Endocrinology
Verified
Journal Article
Open access
PDF file
LALaurence Amar
Laurence Amar
Karel PacakKarel Pacak
Karel Pacak
OSOlivier Steichen
Olivier Steichen
SAScott A. Akker
Scott A. Akker
SASimon J. B. Aylwin
Simon J. B. Aylwin
CLCharlotte Lussey-Lepoutre
Charlotte Lussey-Lepoutre
Approximately 20% of patients diagnosed with a phaeochromocytoma or paraganglioma carry a germline mutation in one of the succinate dehydrogenase (SDHx) genes (SDHA,SDHB,SDHCandSDHD), which encode the four subunits of the SDH enzyme. When a pathogenicSDHxmutation is identified in an affected patient, genetic counselling is proposed for first-degree relatives. Optimal initial evaluation and follow-up of people who are asymptomatic but might carrySDHxmutations have not yet been agreed. Thus, we established an international consensus algorithm of clinical, biochemical and imaging screening at diagnosis and during surveillance for both adults and children. An international panel of 29 experts from 12 countries was assembled, and the Delphi method was used to reach a consensus on 41 statements. This Consensus Statement covers a range of topics, including age of first genetic testing, appropriate biochemical and imaging tests for initial tumour screening and follow-up, screening for rareSDHx-related tumours and management of elderly people who have anSDHxmutation. This Consensus Statement focuses on the management of asymptomaticSDHxmutation carriers and provides clinicians with much-needed guidance. The standardization of practice will enable prospective studies in the near future.

27 August 2018 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NKNORIKO KIMURA
NORIKO KIMURA
KTKazuhiro Takekoshi
Kazuhiro Takekoshi
MNMitsuhide Naruse
Mitsuhide Naruse
Pheochromocytoma (PCC) and sympathetic paraganglioma (PGL) are rare neuroendocrine tumors characterized by catecholamine production in the adrenal medulla and extra-adrenal paraganglia. PCC and PGL (PPGL) with metastasis was termed malignant PPGL. However, the distinction between “benign” and “malignant” PPGLs has been debated. Currently, all PPGLs are believed to have some metastatic potential and are assigned malignant tumors (ICD-O/3) by the WHO Classification of Endocrine Organs (2017, 4th edition). Therefore, the previous categories benign and malignant PPGL have been eliminated in favor of risk stratification approach. The Grading of Adrenal Pheochromocytoma and Paraganglioma (GAPP) is a tool for risk stratification for predicting metastasis and the prognosis of patients. At least 30% of PPGLs are hereditary, with 20 genes identified and genotype-phenotype correlations clarified. Of these genes, VHL, RET and NF1 have been well investigated and are the primary cause of bilateral PCC. In addition, mutation of succinate dehydrogenase gene subunits SDHB and SDHD are strongly correlated with extra-adrenal location, younger age, multiple tumors, metastasis and poor prognosis. Disease stratification by catecholamine phenotype and molecular profiling correlates with histological grading by GAPP. PPGLs should be understood comprehensively based on clinical, biochemical, molecular and pathological data for patient care. A flow chart for pathological diagnosis is included.

6 October 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
HUHironobu Umakoshi
Hironobu Umakoshi
MTMika Tsuiki
Mika Tsuiki
YTYoshiyu Takeda
Yoshiyu Takeda
IKIsao Kurihara
Isao Kurihara
HIHiroshi Itoh
Hiroshi Itoh
JGJPAS Study Group
JPAS Study Group
Context The number of centers with established adrenal venous sampling (AVS) programs for the subtype diagnosis of primary aldosteronism (PA) is limited. Objective Aim was to develop an algorithm for AVS based on subtype prediction by computed tomography (CT) and serum potassium. Design A multi-institutional retrospective cohort study in Japan. Patients A total of 1591 patients with PA were classified into four groups according to CT findings and potassium status. Subtype diagnosis of PA was determined by AVS. Main Outcome Measure Prediction value of the combination of CT findings and potassium status for subtype diagnosis. Results The percentages of unilateral hyperaldosteronism on AVS were higher in patients with unilateral disease on CT than those with bilateral normal results on CT (50.8% vs 14.6%, P < 0.01), and these percentages were higher in those with hypokalemia than those with normokalemia (58.4% vs 11.5%, P < 0.01). The prevalence and odds ratio for unilateral hyperaldosteronism on AVS were as follows: bilateral normal on CT with normokalemia, 6.2% (reference); unilateral disease on CT with normokalemia, 23.8% and 4.8 [95% confidence interval (CI), 3.1 to 7.2]; bilateral normal on CT with hypokalemia, 38.1% and 9.4 (95% CI, 6.2 to 14.1), and unilateral disease on CT with hypokalemia, 70.6% and 36.4 (95% CI, 24.7 to 53.5). Conclusions Patients with PA with bilateral normal results on CT and normokalemia likely have a low prior probability of a lateralized form of AVS and could be treated medically, whereas those with unilateral disease on CT and hypokalemia have a high probability of a lateralized form of AVS.

21 February 2018 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
HUHironobu Umakoshi
Hironobu Umakoshi
TOTatsuki Ogasawara
Tatsuki Ogasawara
YTYoshiyu Takeda
Yoshiyu Takeda
IKIsao Kurihara
Isao Kurihara
HIHiroshi Itoh
Hiroshi Itoh
MNMitsuhide Naruse
Mitsuhide Naruse

3 April 2014 in Journal of Human Hypertension
Verified
Journal Article
Closed access
KNKazutaka Nanba
Kazutaka Nanba
MTM Tsuiki
M Tsuiki
KNK Nakao
K Nakao
ANA Nanba
A Nanba
TUTAKESHI USUI
TAKESHI USUI
MNMitsuhide Naruse
Mitsuhide Naruse